InvestorWire NewsRoom


Articles Category: Biotechnology
Tuesday Mar 21, 2023 - 9:00 am

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable.…

Continue Reading

Monday Mar 20, 2023 - 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults…

Continue Reading

Friday Mar 17, 2023 - 9:45 am

Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care reported a 4% year-over-year revenue increase to approximately $10.1 million for the quarter ended September 30, 2022 The company’s prescription revenue increased 16% year-over-year to almost $9.4 million during that same period In 2022, Progressive Care received nearly $6 million from a strategic investment transaction with NextPlat Corporation The company launched its ClearMetrX platform for 340B third-party administration in 2022 Progressive Care will…

Continue Reading

Monday Mar 13, 2023 - 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety…

Continue Reading

Monday Mar 13, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks With new focus and opportunity, BiondVax now developing…

Continue Reading

Tuesday Mar 07, 2023 - 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in…

Continue Reading

Friday Mar 03, 2023 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Spotlighted in Interview on Making a Positive Social Impact

During interview, Vajdic recounts first steps of journey in the United States CEO points to key lessons he learned that helped him found HeartBeam The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic,…

Continue Reading

Thursday Mar 02, 2023 - 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercially available monoclonal antibodies (“mAbs”), including better specificity and affinity to the target, hyper-thermostability, and potential for more effective and convenient routes of administration Preclinical in vivo data have shown its lead drug candidate, the inhaled anti-SARS-CoV-2 NanoAb,…

Continue Reading

Friday Feb 24, 2023 - 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical studies So far, the preclinical studies have shown that the NanoAb results in significantly milder illness and faster recovery, eliminates the SARS-CoV-2 virus from the lungs, and prevents illness…

Continue Reading

Wednesday Feb 22, 2023 - 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug…

Continue Reading

Wednesday Feb 22, 2023 - 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal

BiondVax Pharmaceuticals is promoting preclinical results of its lead “biobetter” NanoAb drug candidate for conveniently proactively preventing COVID The company’s CEO recently presented the data at the annual BIO CEO & Investor Conference in New York, as well as updates on the company’s pipeline for treating autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration Monoclonal antibody-based drug product Evusheld recently lost its…

Continue Reading

Tuesday Feb 21, 2023 - 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Supports American Heart Month with Commitment to Provide Solutions

President Biden proclaims February as American Heart Month Annual tradition provides opportunity to focus on nationwide problem of heart and blood-vessel diseases HeartBeam is committed to being part of the solution for identifying, treating heart attacks Following a decades-long tradition, President Joseph Biden issued a proclamation from the White House declaring February as American Heart Month ( This nationwide focus on heart health is fully…

Continue Reading

Monday Feb 13, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference

Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8 His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19 treatment Additional results from the study were release in January 2023, indicating that, compared to the control group, hamsters that received the drug…

Continue Reading

Wednesday Feb 08, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth

Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating…

Continue Reading

Monday Feb 06, 2023 - 11:15 am

MetAlert, Inc. (MLRT) – Developing New and Practical GPS Tracking and Other Health Tech Solutions for Real-World Caregivers and Businesses

MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others Attention to consumers has also led to its…

Continue Reading

Monday Feb 06, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidate targeting COVID-19 The FDA recently revoked the sole authorization of a COVID prophylactic, Evusheld, citing the inability of the monoclonal antibody cocktail to neutralize emerging subvariants of the Omicron variant BiondVax’s lead…

Continue Reading

Thursday Feb 02, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Patient Tracking Technology To Gain User Access in Sweden’s Cognitive Care Centers

GPS-enabled location device developer MetAlert provides geographical tracking technology that is discrete and functional through shoe inserts that provide data connectivity to cognitive patient caregivers MetAlert announced in January that it is expanding the reach of its SmartSole flagship product through an agreement with Sweden’s government that was established by distribution partner Posifon AB Government agencies across Europe and in the United States have recognized…

Continue Reading

Monday Jan 30, 2023 - 11:15 am

MetAlert, Inc. (MLRT) Market for Self-actualized Wellness Grows

Wearable wellness technology innovator MetAlert is revitalizing its brand and increasing its product and services portfolio through M&A and other corporate developments designed to improve the company’s healthcare profile The mortality associated with chronic disease can be ameliorated with the use of wearable devices, along with other healthful practices, and the use of wearable wellness technology is expected to continue at an increasing pace More…

Continue Reading

Monday Jan 30, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use…

Continue Reading

Thursday Jan 26, 2023 - 9:45 am

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R) The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police…

Continue Reading

Thursday Jan 26, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO),…

Continue Reading

Tuesday Jan 24, 2023 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO With heart disease consistently being the leading cause of death in the United States (, companies such as HeartBeam (NASDAQ: BEAT) that are…

Continue Reading

Monday Jan 23, 2023 - 10:30 am

MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”) Bertagna also hinted at potential acquisitions by the company, attributing it…

Continue Reading

Thursday Jan 19, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions The acquisition is also…

Continue Reading

Tuesday Jan 17, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where…

Continue Reading

Friday Jan 13, 2023 - 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an…

Continue Reading

Thursday Jan 12, 2023 - 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions…

Continue Reading

Tuesday Jan 10, 2023 - 12:00 pm

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100,…

Continue Reading

Tuesday Jan 10, 2023 - 10:30 am

MetAlert, Inc. (MLRT) Developing Innovative Location-Sensitive Health Monitoring and Supervision Products as It Targets Market Leadership in Telehealth Space

MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market  The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients The company has also launched SmartSole plus(R), which…

Continue Reading

Friday Jan 06, 2023 - 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform

BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward…

Continue Reading

Friday Jan 06, 2023 - 9:45 am

MetAlert, Inc. (MLRT) – Offering More Than Location-Sensitive Health Monitoring Devices

The CDC estimates that by 2060, over 14 million Americans may be diagnosed with Alzheimer’s, up from the current 6.5 million In a surprising study, presented at the 2022 Alzheimer’s Association International Conference, it was noted that this rise could be largely attributed to people’s intake of ultra-processed foods, which was linked to a higher risk of dementia Of the 10,000 participants who took part…

Continue Reading

Wednesday Jan 04, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements

BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”) The technology is exclusively licensed from the prestigious Max Planck Institute for Multidisciplinary Sciences and the…

Continue Reading

Wednesday Jan 04, 2023 - 9:00 am

MetAlert, Inc. (MLRT) Recognizes Link Between Cognition in Aging Population and Use of Hearing Aids

MetAlert has, since its inception, sought to offer quality-of-life improvements to patients and caregivers dealing with Alzheimer’s, dementia, and autism (“ADA”) This focus has led to the company offering products and services within the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring Also important is MetAlert’s offering of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled…

Continue Reading

Wednesday Dec 28, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3% The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed…

Continue Reading

Wednesday Dec 28, 2022 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM…

Continue Reading

Tuesday Dec 27, 2022 - 10:30 am

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up…

Continue Reading

Wednesday Dec 21, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whether symptoms may be the result of a heart attack HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of…

Continue Reading

Tuesday Dec 20, 2022 - 11:15 am

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026 JW-500, a topical treatment for female sexual wellness, is…

Continue Reading

Monday Dec 19, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch Projections for global smartwatch and wearables medical-device markets show consistent upward growth In a world where an estimated 202.6 million people use smartwatches (, the ability to harness the power of…

Continue Reading

Friday Dec 16, 2022 - 11:15 am

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

Ludlow Research ups price target for MetAlert, leading developer of location-sensitive health monitoring devices and wearable technology products, anticipating target between $1 and $1.25 per share MetAlert announced the elimination of all its toxic convertible notes from its balance sheet, which now provides increased stability to its public float The company also shared improved guidance to its NFC operations while also announcing the launch of…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).